You just read:

Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma

News provided by

AbbVie

Dec 04, 2016, 19:30 ET